CAC2 Childhood Cancer Community News Digest (June 20-26)

Assorted News from Last Week: Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia’s paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly-aggressive childhood brain cancer. Bridge therapy ahead of autologous stem cell transplantation (ASCT) consolidation may benefit certain high-risk neuroblastoma patients with residual disease following induction regimens, according to a multicenter retrospective study. Novartis announced the FDA has granted accelerated approval to the BRAF inhibitor dabrafenib (Tafinlar) combined with the MEK inhibitor trametinib […]

Read more

CAC2 Childhood Cancer Community News Digest (June 13-19)

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. On the basis of extensive experience in recent years, most notably with mAbs, persisting with administering myeloablative chemotherapy as the standard to treat children with high risk neuroblastoma is not […]

Read more

CAC2 Childhood Cancer Community News Digest (June 6-12)

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. CAC2 Supporting Organization Member Day One Biopharmaceuticals mid-stage data show an overall response rate of 64% and clinical benefit rate of 91% in the first 22 evaluable patients treated with […]

Read more

CAC2 Childhood Cancer Community News Digest (May 30-June 5)

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. A combination of brentuximab vedotin (Adcetris) and chemotherapy was safe and effective in pediatric patients (up to age 21 years) with newly diagnosed high-risk Hodgkin lymphoma. Cancer in lymph nodes […]

Read more

CAC2 Childhood Cancer Community News Digest (May 23-30)

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. On May 20, 2022, the Food and Drug Administration approved azacitidine (Vidaza, Celgene Corp.) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML). From Forbes:  Young adults who have […]

Read more

CAC2 Childhood Cancer Community News Digest (May 9-22)

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. On May 20, 2022, the Food and Drug Administration approved azacitidine (Vidaza, Celgene Corp.) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML). Pediatric cancer survivorship lessons 42 years […]

Read more

CAC2 Childhood Cancer Community News Digest (May 2-8)

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. Recently, CCDI launched the CCDI Data Catalog web application, part of the CCDI Data Ecosystem. Adolescent and young adult (AYA) cancer survivors have a significantly increased risk for developing a […]

Read more

Guest Blog–National Cancer Institute Launches the CCDI Childhood Cancer Data Catalog

The Childhood Cancer Data Catalog is a searchable database of National Cancer Institute and other pediatric cancer resources and is part of NCI’s Childhood Cancer Data Initiative (CCDI), which is building a community centered around childhood cancer care and research data.  Through enhanced data sharing, investigators can improve understanding of cancer biology, preventive measures, treatment, quality of life, and survivorship, as well as ensure that researchers learn from every child with cancer. Recently, CCDI launched the CCDI Data Catalog web application, part of the CCDI Data Ecosystem.  The CCDI Childhood Cancer Data Catalog is an inventory of pediatric oncology data resources, [...] Read more

CAC2 Childhood Cancer Community News Digest (April 25-May 1)

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. The Alliance for Childhood Cancer sends its thanks for a fantastic Action Day on April 28!  Nearly 300 advocates from 39 states and Washington, DC participated and attended almost 200 […]

Read more

CAC2 News–Great.com Interviews Coalition Against Childhood Cancer About A Future Without Childhood Cancers

Danielle Riberio from Great.com interviewed Coalition Against Childhood Cancer as part of their ‘Great.com Talks With…’ podcast. This series is an antidote to negative news stories that aims to shed light on organizations and experts whose work is making a positive impact on the world. Families affected by childhood cancer face untold challenges. From having to sacrifice work to paying huge medical bills, only a small number of families can afford to make these sacrifices. For the vast majority that cannot, life can be extremely difficult for both patient and family members. In this episode, Danielle talked with Vickie Buenger, […]

Read more